GENE ONLINE|News &
Opinion
Blog

2018-12-17| Trials & Approvals

Novartis’s Ligelizumab Progresses to Phase III Trial

by Rajaneesh K. Gopinath
Share To

By Rajaneesh K. Gopinath, Ph.D.

After it’s strong showing in a Phase IIb trial, the monoclonal antibody now moves to the next stage of its development as an effective therapy for chronic spontaneous urticaria (CSU).

Chronic Urticaria is an allergic skin disease that is characterized by the formation of wheals and angioedema. Chronic spontaneous urticaria (CSU) is one of the subtypes of the disease which could occur unpredictably without a trigger. Omalizumab (Xolair), is a prescribed treatment for the condition. It is a humanized monoclonal antibody that binds to Immunoglobulin E (IgE) and reduces allergic symptoms. The drug is used for the treatment of various allergic reactions including Asthma. It is considered a breakthrough drug and was recently recommended by a global guideline as an add-on therapy for CSU patients who are unresponsive to antihistamines. Xolair is marketed all over the world and in the US, it is co-promoted by Novartis Pharmaceuticals and Genentech Inc.

In recent times though, Novartis is developing yet another humanized anti-IgE monoclonal antibody called ligelizumab, for the treatment of allergic and autoimmune diseases. After promising results in a Phase IIb clinical trial comprising 382 patients, it is now advancing to Phase III trials. In the placebo- and active-controlled Phase IIb trial, ligelizumab outperformed omalizumab and met its primary endpoint by demonstrating a clear dose-response relationship. It bound IgE with greater affinity than omalizumab, and this translated into greater therapeutic efficacy. Ligelizumab achieved a rapid onset of action and improved and sustained efficacy. The results were announced at the 27th EADV Congress 2018 in Paris.

On December 4th, Novartis announced the initiation of multi-center, randomized, double-blind, active- and placebo-controlled Phase III trials – PEARL1 and PEARL 2. More than 2,000 patients will initially be randomized to ligelizumab dose A and B, omalizumab 300mg with the treatment given every 4 weeks for one year. Patients initially randomized to placebo will be switched to ligelizumab dose B starting week 24 until week 52. The primary outcome will measure absolute change from baseline in Urticaria Activity Score (UAS7) at Week 12.

Eric Hughes, Global Development Unit Head, Immunology, Hepatology and Dermatology expressed his excitement. “Novartis is committed to leveraging our strong heritage and expertise in immuno-dermatology to reimagine and discover potential new treatments which can benefit patients,” he said in a statement. “By initiating ligelizumab to Phase III studies we continue to honor that commitment”.

 

References
  1. https://www.novartis.com/news/media-releases/novartis-advances-ligelizumab-qge031-urticaria-phase-iii-basis-strong-phase-ii-head-head-data
  2. https://www.mdedge.com/edermatologynews/article/183878/urticaria/ligelizumab-outperformed-omalizumab-refractory-chronic
  3. https://www.novartis.com/news/media-releases/novartis-xolairr-recommended-new-global-chronic-urticaria-guideline

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Novartis Shifts Gear To Phase 3 For Anti-Malaria Drug
2022-11-24
AstraZeneca’s Treatment for Rare Throat Disease, Eosinophilic esophagitis, Fails Primary Endpoint
2022-10-25
Genentech Unveils Positive Two-Year Data For Spinal Muscular Atrophy Drug
2022-10-13
LATEST
Repairing Genetic Mutations in Neurological Diseases with RNA Targeting Strategy
2022-11-25
AstraZeneca Thailand Wins Two ACES Awards 2022: “Industry Champions of the Year” and “Community Initiative”
2022-11-24
Mabwell Announces the U.S. FDA approval of 9MW3011 (FIC) for IND
2022-11-24
Novartis Shifts Gear To Phase 3 For Anti-Malaria Drug
2022-11-24
Moving Past Animal Models with Better Data for Drug Discovery
2022-11-23
IonOpticks ushers in a new age of proteomics with Aurora Frontier
2022-11-23
Korea Ginseng Corp.: As an adaptogenic herb, Korean red ginseng boosts the human immune response
2022-11-23
EVENT
2022-12-01
BIOCHINA 2022
Online
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!